Epigenetic regulation of drug transporter expression in human tissues

ABSTRACT Introduction: Drug transporters are expressed in a number of tissues such as the intestine, liver, and kidney, and play key roles in drug absorption, distribution, and excretion. Variations in drug transporter gene expression significantly contribute to interindividual differences in drug responses. Epigenetic regulation of drug transporter genes has recently emerged as an important mechanism. Epigenetic regulation alters the expression of genes without changing DNA sequences. Epigenetic control mechanisms are associated with DNA methylation, histone modifications, and microRNAs. Herein we discuss recent advances in the study of the transcriptional and post-transcriptional mechanisms of drug transporters with a focus on epigenetic regulation. Areas covered: This review summarizes recent research on the epigenetic regulation of drug transporter genes, and highlights the importance of identifying novel biomarkers based on epigenetics for use in individualized drug therapy. Expert opinion: Researchers are actively attempting to elucidate the epigenetic mechanisms that control the expression of drug transporters, which affect the pharmacokinetics of drugs. Current evidence suggests that epigenetic changes play an important role in drug transporter function. A clearer understanding of epigenetic regulation in drug transporter genes will provide an insight into novel approaches to individualized drug therapy.

[1]  I. Ieiri,et al.  Circulating intestine-derived exosomal miR-328 in plasma, a possible biomarker for estimating BCRP function in the human intestines , 2016, Scientific Reports.

[2]  R. Benndorf,et al.  The C421A (Q141K) polymorphism enhances the 3'-untranslated region (3'-UTR)-dependent regulation of ATP-binding cassette transporter ABCG2. , 2016, Biochemical pharmacology.

[3]  K. Drerup,et al.  Length variants of the ABCB1 3'-UTR and loss of miRNA binding sites: possible consequences in regulation and pharmacotherapy resistance. , 2016, Pharmacogenomics.

[4]  R. de Cabo,et al.  miR-27b inhibits LDLR and ABCA1 expression but does not influence plasma and hepatic lipid levels in mice. , 2015, Atherosclerosis.

[5]  K. To,et al.  Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer. , 2015, Experimental cell research.

[6]  Y. Li,et al.  Interindividual epigenetic variation in ABCB1 promoter and its relationship with ABCB1 expression and function in healthy Chinese subjects. , 2015, British journal of clinical pharmacology.

[7]  R. de Cabo,et al.  Identification of miR-148a as a novel regulator of cholesterol metabolism , 2015, Nature Medicine.

[8]  Hui Zhao,et al.  MicroRNA-134 modulates resistance to doxorubicin in human breast cancer cells by downregulating ABCC1 , 2015, Biotechnology Letters.

[9]  Jie Huang,et al.  miR‐7 modulates chemoresistance of small cell lung cancer by repressing MRP1/ABCC1 , 2015, International journal of experimental pathology.

[10]  X. Ruan,et al.  MicroRNA-101 overexpression by IL-6 and TNF-α inhibits cholesterol efflux by suppressing ATP-binding cassette transporter A1 expression. , 2015, Experimental cell research.

[11]  M. Hayden,et al.  Corrigendum to “Direct intracerebral delivery of a miR-33 antisense oligonucleotide into mouse brain increases brain ABCA1 expression’’ [Neuroscience Letters 598 (2015) 66–72] , 2015, Neuroscience Letters.

[12]  Jia Yu,et al.  Involvement of miR-133a and miR-326 in ADM resistance of HepG2 through modulating expression of ABCC1 , 2015, Journal of drug targeting.

[13]  P. Sorensen,et al.  Direct intracerebral delivery of a miR-33 antisense oligonucelotide into mouse brain increases brain ABCA1 expression , 2015, Neuroscience Letters.

[14]  D. He,et al.  miR-124 represses FZD5 to attenuate P-glycoprotein-mediated chemo-resistance in renal cell carcinoma , 2015, Tumor Biology.

[15]  B. W. van Balkom,et al.  Quantitative and qualitative analysis of small RNAs in human endothelial cells and exosomes provides insights into localized RNA processing, degradation and sorting , 2015, Journal of extracellular vesicles.

[16]  M. Filip,et al.  A Comprehensive View of the Epigenetic Landscape. Part II: Histone Post-translational Modification, Nucleosome Level, and Chromatin Regulation by ncRNAs , 2014, Neurotoxicity Research.

[17]  T. Abe,et al.  Organic anion transporting polypeptides 1B1 and 1B3 play an important role in uremic toxin handling and drug-uremic toxin interactions in the liver. , 2014, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[18]  F. Rödel,et al.  Quantitative Analysis of Liposomal Heat Shock Protein 70 (Hsp70) in the Blood of Tumor Patients Using a Novel LipHsp70 ELISA , 2014 .

[19]  M. Bonder,et al.  Genetic and epigenetic regulation of gene expression in fetal and adult human livers , 2014, BMC Genomics.

[20]  S. Cai,et al.  miR200c Attenuates P-gp–Mediated MDR and Metastasis by Targeting JNK2/c-Jun Signaling Pathway in Colorectal Cancer , 2014, Molecular Cancer Therapeutics.

[21]  Min Zhang,et al.  MicroRNA-19b promotes macrophage cholesterol accumulation and aortic atherosclerosis by targeting ATP-binding cassette transporter A1. , 2014, Atherosclerosis.

[22]  J. Huwyler,et al.  Prediction of Organic Anion-Transporting Polypeptide 1B1- and 1B3-Mediated Hepatic Uptake of Statins Based on Transporter Protein Expression and Activity Data , 2014, Drug Metabolism and Disposition.

[23]  Taosheng Chen,et al.  miR-137 regulates the constitutive androstane receptor and modulates doxorubicin sensitivity in parental and doxorubicin-resistant neuroblastoma cells , 2014, Oncogene.

[24]  Y. Shang,et al.  miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1 , 2014, Oncogene.

[25]  Taotao Ma,et al.  MiR-27a modulates the MDR1/P-glycoprotein expression by inhibiting FZD7/β-catenin pathway in hepatocellular carcinoma cells. , 2013, Cellular signalling.

[26]  Yiqiao Hu,et al.  Changes in the Expression of miR-381 and miR-495 Are Inversely Associated with the Expression of the MDR1 Gene and Development of Multi-Drug Resistance , 2013, PloS one.

[27]  Q. Qu,et al.  Different Involvement of Promoter Methylation in the Expression of Organic Cation/Carnitine Transporter 2 (OCTN2) in Cancer Cell Lines , 2013, PloS one.

[28]  Lin Zhao,et al.  MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2). , 2013, Cancer letters.

[29]  Yuzhuo Pan,et al.  Small Nucleolar RNA-Derived MicroRNA hsa-miR-1291 Modulates Cellular Drug Disposition through Direct Targeting of ABC Transporter ABCC1 , 2013, Drug Metabolism And Disposition.

[30]  H. Takane,et al.  Association between DNA Methylation in the miR-328 5’-Flanking Region and Inter-individual Differences in miR-328 and BCRP Expression in Human Placenta , 2013, PloS one.

[31]  Yun-Feng Geng,et al.  MiR-223 modulates multidrug resistance via downregulation of ABCB1 in hepatocellular carcinoma cells , 2013, Experimental biology and medicine.

[32]  N. Hosoe,et al.  Correction: Overexpression of miR-142-5p and miR-155 in Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma Resistant to Helicobacter pylori Eradication , 2013, PLoS ONE.

[33]  Chao-ke Tang,et al.  Posttranscriptional regulation of ATP-binding cassette transporter A1 in lipid metabolism. , 2013, DNA and cell biology.

[34]  H. Kusuhara,et al.  Epigenetic Regulation of Organic Anion Transporting Polypeptide 1B3 in Cancer Cell Lines , 2013, Pharmaceutical Research.

[35]  Lin Zhao,et al.  MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2) , 2013, Breast Cancer Research and Treatment.

[36]  P. Edwards,et al.  MicroRNA-144 Regulates Hepatic ATP Binding Cassette Transporter A1 and Plasma High-Density Lipoprotein After Activation of the Nuclear Receptor Farnesoid X Receptor , 2013, Circulation research.

[37]  R. A. Reid,et al.  Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group. , 2013, Nature chemical biology.

[38]  G. Fu,et al.  MiR-142-3p functions as a tumor suppressor by targeting CD133, ABCG2, and Lgr5 in colon cancer cells , 2013, Journal of Molecular Medicine.

[39]  Lianfeng Zhang,et al.  Long-Term Cisplatin Exposure Promotes Methylation of the OCT1 Gene in Human Esophageal Cancer Cells , 2013, Digestive Diseases and Sciences.

[40]  Misato Yamamoto,et al.  MicroRNA-145 Post-transcriptionally Regulates the Expression and Function of P-glycoprotein in Intestinal Epithelial Cells , 2013, Molecular Pharmacology.

[41]  H. Kusuhara,et al.  DNA Methylation and Histone Modification Profiles of Mouse Organic Anion Transporting Polypeptides , 2013, Drug Metabolism and Disposition.

[42]  M. Ingelman-Sundberg,et al.  Epigenomics and Interindividual Differences in Drug Response , 2012, Clinical pharmacology and therapeutics.

[43]  Jun-qing Chen,et al.  Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer , 2012, Medical Oncology.

[44]  M. Gottesman,et al.  Regulation and Expression of the ATP‐Binding Cassette Transporter ABCG2 in Human Embryonic Stem Cells , 2012, Stem cells.

[45]  Huijun Sun,et al.  Inhibitory effect of JBP485 on renal excretion of acyclovir by the inhibition of OAT1 and OAT3. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[46]  Jianwen Liu,et al.  miR-297 modulates multidrug resistance in human colorectal carcinoma by down-regulating MRP-2. , 2012, The Biochemical journal.

[47]  Hongjing Wang,et al.  Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance. , 2012, Oncology reports.

[48]  X. Wan,et al.  MicroRNA‐199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer‐initiating cells , 2012, The FEBS journal.

[49]  Sidhartha Hazari,et al.  Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. , 2012, The American journal of pathology.

[50]  K. Mealey.  ABCG2 transporter: therapeutic and physiologic implications in veterinary species. , 2012, Journal of veterinary pharmacology and therapeutics.

[51]  I. Boros,et al.  Elevated level of lysine 9‐acetylated histone H3 at the MDR1 promoter in multidrug‐resistant cells , 2012, Cancer science.

[52]  S. Iwakawa,et al.  Different involvement of DNA methylation and histone deacetylation in the expression of solute-carrier transporters in 4 colon cancer cell lines. , 2012, Biological & pharmaceutical bulletin.

[53]  H. Kusuhara,et al.  Regulation of Tissue-Specific Expression of Renal Organic Anion Transporters by Hepatocyte Nuclear Factor 1 α/β and DNA Methylation , 2012, Journal of Pharmacology and Experimental Therapeutics.

[54]  I. Cascorbi,et al.  MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression , 2012, Pharmacogenetics and genomics.

[55]  I. Yoshino,et al.  Identification of a new organic anion transporting polypeptide 1B3 mRNA isoform primarily expressed in human cancerous tissues and cells. , 2012, Biochemical and biophysical research communications.

[56]  Jianwen Liu,et al.  Role for Class I histone deacetylases in multidrug resistance. , 2012, Experimental cell research.

[57]  Ute Hofmann,et al.  DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma , 2011, Genome Medicine.

[58]  T. Ferrin,et al.  Genetic and Epigenetic Regulation of the Organic Cation Transporter 3, SLC22A3 , 2011, The Pharmacogenomics Journal.

[59]  Bo W. Han,et al.  Down-regulated miR-331–5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia , 2011, Journal of cellular and molecular medicine.

[60]  F. Sharom.  The P-glycoprotein multidrug transporter. , 2011, Essays in biochemistry.

[61]  I. Ieiri,et al.  Interindividual differences in placental expression of the SLC22A2 (OCT2) gene: relationship to epigenetic variations in the 5'-upstream regulatory region. , 2011, Journal of pharmaceutical sciences.

[62]  I. Cascorbi,et al.  Down-Regulation of ATP-Binding Cassette C2 Protein Expression in HepG2 Cells after Rifampicin Treatment Is Mediated by MicroRNA-379 , 2011, Molecular Pharmacology.

[63]  M. Baccarani,et al.  c-MYC Oncoprotein Dictates Transcriptional Profiles of ATP-Binding Cassette Transporter Genes in Chronic Myelogenous Leukemia CD34+ Hematopoietic Progenitor Cells , 2011, Molecular Cancer Research.

[64]  Xin Li,et al.  Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells. , 2011, Biochemical pharmacology.

[65]  Su-Nam Kim,et al.  HDAC inhibitors downregulate MRP2 expression in multidrug resistant cancer cells: implication for chemosensitization. , 2011, International journal of oncology.

[66]  K. Scotto,et al.  Histone methyltransferase MLL1 regulates MDR1 transcription and chemoresistance. , 2010, Cancer research.

[67]  W. Jin,et al.  UHRF1 inhibits MDR1 gene transcription and sensitizes breast cancer cells to anticancer drugs , 2010, Breast Cancer Research and Treatment.

[68]  Andrey Golubov,et al.  Alterations of microRNAs and their targets are associated with acquired resistance of MCF‐7 breast cancer cells to cisplatin , 2010, International journal of cancer.

[69]  Jing Cai,et al.  MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells. , 2010, Gynecologic oncology.

[70]  Hongwei Zhang,et al.  Down-Regulation of miR-27a Might Reverse Multidrug Resistance of Esophageal Squamous Cell Carcinoma , 2010, Digestive Diseases and Sciences.

[71]  Xiaohong Zhao,et al.  miR-138 might reverse multidrug resistance of leukemia cells. , 2010, Leukemia research.

[72]  Swati S. More,et al.  Organic Cation Transporters Modulate the Uptake and Cytotoxicity of Picoplatin, a Third-Generation Platinum Analogue , 2010, Molecular Cancer Therapeutics.

[73]  Hyunsuk Shim,et al.  Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. , 2010, Biochemical pharmacology.

[74]  J. Sprowl,et al.  The temporal relationship between ABCB1 promoter hypomethylation, ABCB1 expression and acquisition of drug resistance , 2010, The Pharmacogenomics Journal.

[75]  Y. Assaraf,et al.  Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance. , 2009, Neoplasia.

[76]  D. Keppler,et al.  Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver , 2009, Hepatology.

[77]  M. Lübbert,et al.  Histone Deacetylase Inhibitors Induce a Very Broad, Pleiotropic Anticancer Drug Resistance Phenotype in Acute Myeloid Leukemia Cells by Modulation of Multiple ABC Transporter Genes , 2009, Clinical Cancer Research.

[78]  Marilyn E Morris,et al.  MicroRNA-328 Negatively Regulates the Expression of Breast Cancer Resistance Protein (BCRP/ABCG2) in Human Cancer Cells , 2009, Molecular Pharmacology.

[79]  D. Seo,et al.  Histone Deacetylase Inhibitor Induction of P-Glycoprotein Transcription Requires Both Histone Deacetylase 1 Dissociation and Recruitment of CAAT/Enhancer Binding Protein β and pCAF to the Promoter Region , 2009, Molecular Cancer Research.

[80]  E. Morii,et al.  Synergistic effect of interleukin-6 and endoplasmic reticulum stress inducers on the high level of ABCG2 expression in plasma cells , 2009, Laboratory Investigation.

[81]  Yariv Yogev,et al.  Serum MicroRNAs Are Promising Novel Biomarkers , 2008, PloS one.

[82]  Xiuping Liu,et al.  Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. , 2008, Biochemical pharmacology.

[83]  K. Reed,et al.  Hypermethylation of the ABCB1 downstream gene promoter accompanies ABCB1 gene amplification and increased expression in docetaxel-resistant MCF-7 breast tumor cells , 2008, Epigenetics.

[84]  C. Choi,et al.  Epigenetic mechanisms involved in differential MDR1 mRNA expression between gastric and colon cancer cell lines and rationales for clinical chemotherapy , 2008, BMC gastroenterology.

[85]  W. Duan,et al.  Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. , 2008, Current medicinal chemistry.

[86]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[87]  Olga Kovalchuk,et al.  Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin , 2008, Molecular Cancer Therapeutics.

[88]  O. Ogawa,et al.  Kidney-specific expression of human organic cation transporter 2 (OCT2/SLC22A2) is regulated by DNA methylation. , 2008, American journal of physiology. Renal physiology.

[89]  T. Litman,et al.  Regulation of ABCG2 Expression at the 3′ Untranslated Region of Its mRNA through Modulation of Transcript Stability and Protein Translation by a Putative MicroRNA in the S1 Colon Cancer Cell Line , 2008, Molecular and Cellular Biology.

[90]  K. Yanagihara,et al.  Methylation status of breast cancer resistance protein detected by methylation‐specific polymerase chain reaction analysis is correlated inversely with its expression in drug‐resistant lung cancer cells , 2008, Cancer.

[91]  S. Bates,et al.  Histone Modifications at the ABCG2 Promoter following Treatment with Histone Deacetylase Inhibitor Mirror Those in Multidrug-Resistant Cells , 2008, Molecular Cancer Research.

[92]  Magnus Ingelman-Sundberg,et al.  Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. , 2007, Pharmacology & therapeutics.

[93]  J. Foekens,et al.  Production of P‐glycoprotein from the MDR1 upstream promoter is insufficient to affect the response to first‐line chemotherapy in advanced breast cancer , 2007, International journal of cancer.

[94]  M. Merten,et al.  Cobalamin Potentiates Vinblastine Cytotoxicity Through Downregulation of mdr-1 Gene Expression in HepG2 Cells , 2007, Cellular Physiology and Biochemistry.

[95]  Per Artursson,et al.  Expression of Thirty-six Drug Transporter Genes in Human Intestine, Liver, Kidney, and Organotypic Cell Lines , 2007, Drug Metabolism and Disposition.

[96]  B. Stieger,et al.  Bosentan Is a Substrate of Human OATP1B1 and OATP1B3: Inhibition of Hepatic Uptake as the Common Mechanism of Its Interactions with Cyclosporin A, Rifampicin, and Sildenafil , 2007, Drug Metabolism and Disposition.

[97]  G. Breuzard,et al.  The histone deacetylase inhibitor trichostatin A downregulates human MDR1 (ABCB1) gene expression by a transcription-dependent mechanism in a drug-resistant small cell lung carcinoma cell line model , 2007, British Journal of Cancer.

[98]  Jian Zhang,et al.  The establishment of two paclitaxel‐resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines , 2007, The Prostate.

[99]  A. Trussardi-Régnier,et al.  Differential modulation of nuclear texture, histone acetylation, and MDR1 gene expression in human drug-sensitive and -resistant OV1 cell lines. , 2007, International journal of oncology.

[100]  Lippincott-Schwartz,et al.  Supporting Online Material Materials and Methods Som Text Figs. S1 to S8 Table S1 Movies S1 to S3 a " Silent " Polymorphism in the Mdr1 Gene Changes Substrate Specificity Corrected 30 November 2007; See Last Page , 2022 .

[101]  M. Schell,et al.  ABCG2 expression, function, and promoter methylation in human multiple myeloma. , 2006, Blood.

[102]  S. Bates,et al.  Aberrant Promoter Methylation of the ABCG2 Gene in Renal Carcinoma , 2006, Molecular and Cellular Biology.

[103]  W. Sadee,et al.  Searching for polymorphisms that affect gene expression and mRNA processing: Example ABCB1 (MDR1) , 2006, The AAPS Journal.

[104]  H. Kusuhara,et al.  Regulation of the Expression of Human Organic Anion Transporter 3 by Hepatocyte Nuclear Factor 1α/β and DNA Methylation , 2006, Molecular Pharmacology.

[105]  T. Fojo,et al.  Aberrant transcription from an unrelated promoter can result in MDR-1 expression following drug selection in vitro and in relapsed lymphoma samples. , 2005, Cancer research.

[106]  E. Olson,et al.  Control of cardiac growth by histone acetylation/deacetylation. , 2005, Circulation research.

[107]  J. Zalcberg,et al.  Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs , 2005, Oncogene.

[108]  T. Fojo,et al.  Genetic and epigenetic modeling of the origins of multidrug-resistant cells in a human sarcoma cell line. , 2005, Cancer research.

[109]  J. Heinecke,et al.  ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease. , 2005, Physiological reviews.

[110]  Yuichi Sugiyama,et al.  A Species Difference in the Transport Activities of H2 Receptor Antagonists by Rat and Human Renal Organic Anion and Cation Transporters , 2005, Journal of Pharmacology and Experimental Therapeutics.

[111]  K. Inui,et al.  Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1. , 2005, Biochemical pharmacology.

[112]  K. Robertson.  DNA methylation and human disease , 2005, Nature Reviews Genetics.

[113]  M. Grever,et al.  Chemoresistance to Depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-Ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] Is Mediated by Reversible MDR1 Induction in Human Cancer Cell Lines , 2005, Journal of Pharmacology and Experimental Therapeutics.

[114]  Arturas Petronis,et al.  Phenotypic differences in genetically identical organisms: the epigenetic perspective. , 2005, Human molecular genetics.

[115]  Masahiro Okuda,et al.  Metformin Transport by Renal Basolateral Organic Cation Transporter hOCT2 , 2005, Pharmaceutical Research.

[116]  B. Nordestgaard,et al.  Genetic variation in ABC transporter A1 contributes to HDL cholesterol in the general population. , 2004, The Journal of clinical investigation.

[117]  Mukesh Verma,et al.  Challenges for Biomarkers in Cancer Detection , 2004, Annals of the New York Academy of Sciences.

[118]  A. Marzo,et al.  MDR1 Promoter Hypermethylation in MCF-7 Human Breast Cancer Cells: Changes in Chromatin Structure Induced by Treatment with 5-Aza-Cytidine , 2004, Cancer biology & therapy.

[119]  R. Kim.  Drugs as P-glycoprotein substrates, inhibitors, and inducers , 2002, Drug metabolism reviews.

[120]  R. Lawn,et al.  ABCA1. The gatekeeper for eliminating excess tissue cholesterol. , 2001, Journal of lipid research.

[121]  T. Efferth,et al.  5-Azacytidine modulates the response of sensitive and multidrug-resistant K562 leukemic cells to cytostatic drugs. , 2001, Blood cells, molecules & diseases.

[122]  G. Seydoux,et al.  PIE-1 is a bifunctional protein that regulates maternal and zygotic gene expression in the embryonic germ line of Caenorhabditis elegans. , 2001, Genes & development.

[123]  I. Pastan,et al.  The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation. , 1987, The Journal of biological chemistry.

[124]  S. Bates,et al.  Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy. , 2012, Discovery medicine.

[125]  F. Wang,et al.  Up-regulation of ABCB1/P-glycoprotein by escaping promoter hypermethylation indicates poor prognosis in hematologic malignancy patients with and without bone marrow transplantation. , 2011, Leukemia research.

[126]  Ryan E. Temel,et al.  Inhibition of miR-33 a / b in non-human primates raises plasma HDL and lowers VLDL triglycerides , 2011 .

[127]  中道 尚人.  Synergistic effect of interleukin-6 and endoplasmic reticulum stress inducers on the high level of ABCG2 expression in plasma cells , 2010 .

[128]  S. Higuchi,et al.  Epigenetic regulation of genes encoding drug-metabolizing enzymes and transporters; DNA methylation and other mechanisms. , 2008, Current drug metabolism.

[129]  P. Molloy,et al.  DNA hypomethylation and human diseases. , 2007, Biochimica et biophysica acta.

[130]  H. Kusuhara,et al.  Regulation of the expression of human organic anion transporter 3 by hepatocyte nuclear factor 1alpha/beta and DNA methylation. , 2006, Molecular pharmacology.

[131]  Q. Feng,et al.  The MeCP1 complex represses transcription through preferential binding, remodeling, and deacetylating methylated nucleosomes. , 2001, Genes & development.